This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Worst IPO Peddling Isn't Social Media

"Biofuels is the worst IPO class in terms of performance. They have all really tanked," said Francis Gaskins of IPODesktop.

"Social media stays up because it has a slew of users who don't understand valuation metrics and these people don't care about valuation and weren't around for the bust," Gaskins added, explaining why a Groupon (GRPN) might take much longer to bottom out from IPO levels.

The good news is that Ceres IPO delay, and recent pricing disappointments in these IPOs, shows that investors are getting a little more wary.

"Investors aren't buying future promises anymore. These companies can still go public but the price to book value will be a lot less than the investment bankers told them," Gaskins said. "Ceres delayed because they couldn't IPO at the price Goldman told them they would -- Goldman bamboozled them," he added. Though at least, as of yet, it hasn't bamboozled the investing public with the Ceres offering.

Ceres plans to go public next week at a reduced price range of $16 to $17, down from $21 to $23 previously. Gaskins noted that strength in the Dow Jones Industrial Average last April and May allowed IPO underwriters to juice valuations, but now as the Dow is back at a similar level near 13,000, Ceres is lowering its expected IPO value.

Jeff Obsorne, analyst at Stifel, said that the primary risk in this space is that all of these technologies that work great in the test tube or at the demonstration stage don't easily scale to a commercial level on a cost-competitive basis. This was more or less the bottom line in the Amyris revelation this week and its pulling of guidance and scaling back of expansion plans.

The IPOs of these biofuels companies have been predicated on cash flow models built for years out from the IPO date -- as far out as 2014 and 2015. Any time a major milestone on the way to that cash flow model isn't met, all of the IPO assumptions are upset. Amyris's future cash flow was built on a model that assumed its business would scale across a specific number of commercial plants, and now, that assumption is no longer looking like reality.

Investors can still make a quick buck, but it's hard to justify why an investor would buy the next biofuels IPO given the sector's track record.

"The events that Amyris experienced in the last 6 months have a risk of occurring across many of the bioproducts companies that are trading today and the 10-15 that are in registration for an IPO," Osborne wrote on Friday.
2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
KIOR $0.01 -3.45%
AMRS $1.01 0.00%
CDXS $3.34 0.00%
GEVO $0.26 0.00%
GS $164.50 0.13%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs